Статья 28Регламент № 1234/2008 Комиссии Европейских сообществ
Актуально на 03.11.2026.
Как цитировать: Статья 28. Регламент N 1234/2008 Комиссии Европейских сообществ. 1234/2008. https://bukva.ai/docs/reglament-12342008/statya-28
Настоящий Регламент вступает в силу на 20-й день после его опубликования в Официальном Журнале Европейского Союза.
Он применяется с 1 января 2010 г.
Путем частичного отступления от второго подпараграфа рекомендации по непредвиденным изменениям, предусмотренные в Статье 5, могут быть запрошены, отправлены и опубликованы с даты вступления в силу, упомянутой в первом подпараграфе.
Настоящий Регламент имеет обязательную силу в полном объеме и подлежит прямому применению во всех государствах-членах ЕС.
1. Изменения в активном(ых) веществе(ах):
(a) замена химически активных веществ путем различия в солях/сложных эфирах/производных, с тем же терапевтическим действием, когда эффективность/безопасность характеристик существенно не различается;
(b) замена на другие изомеры, различные смеси изомеров, смеси изолированных изомеров (например, рацемат, различающийся на один энантиомер), когда эффективность/безопасность характеристик существенно не различается;
(c) замена биологически активного вещества с одной из нескольких различных молекулярных структур, когда эффективность/безопасность характеристик существенно не различается, за исключением:
- изменений в активном веществе сезонной, препандемической и пандемической вакцины против человеческого гриппа;
- замены или дополнения серотипа, штамма, антигена или кодирующей последовательности или сочетания серотипов, штаммов или антигенов или кодирующих последовательностей для вакцин против коронавируса человека;
- замены или дополнения серотипа, штамма, антигена или сочетания серотипов, штаммов или антигенов для ветеринарных вакцин против птичьего гриппа, ящура или катаральной лихорадки овец;
- замены штаммов для ветеринарных вакцин против лошадиного гриппа;
(d) изменения бациллоносителя, используемого для изготовления антигена или исходного материала, включая главный банк клеток из другого источника, где эффективность/безопасность характеристик существенно не различается;
(e) новый лиганд или механизм сцепления для радиофармацевтики, когда эффективность/безопасность характеристик существенно не различается;
(f) изменения в экстракциях растворителей или в соотношении растительных элементов в лекарственных средствах на травах, когда эффективность/безопасность характеристик существенно не различается.
2. Изменения в степени воздействия, лекарственной форме и способе применения:
(b) изменения фармакокинетики, например, изменения в скорости выделения лекарственных средств;
(c) изменение или дополнение новой степени воздействия/силы воздействия;
(d) изменение или дополнение новой лекарственной формы;
(e) изменение или дополнение нового способа применения <*>.
<*> В парентеральных способах применения различают внутриартериальные, внутривенные, внутримышечные, подкожные и другие. Способы применения, используемые для вакцинации для домашней птицы, респираторно, орально или путем введения в глаза (распыление), считаются эквивалентными способами применения лекарственных средств.
3. Другие изменения, характерные для ветеринарных лекарственных средств, которые применяются в продовольственном животноводстве: изменение или дополнение целевых видов.
1. Следующие изменения должны быть классифицированы как незначительные изменения по типу IA:
(a) изменения чисто административного характера, связанные с идентификацией и контактной информацией об:
- обладателе;
- изготовителе или поставщике любого сырья, реагентов, промежуточных активных веществ, используемых в процессе производства или в готовой продукции;
(b) изменения, связанные с удалением любой из сторон производства, включая активное вещество, промежуточную и готовую продукцию, сторону упаковки; производителя, отвечающего за выпуск партии; стороны по регулированию дозировки;
(c) изменения, связанные с незначительными изменениями по утверждению физико-химических процедур тестирования, когда обновленные процедуры являются по крайней мере эквивалентными предыдущим процедурам испытания; соответствующие проверки были проведены и их результат показывает, что обновленная процедура проверки по крайней мере эквивалентна предыдущей;
(d) изменения, связанные с изменениями технических характеристик активного вещества или вспомогательного вещества, для того, чтобы выполнить обновление соответствующей монографии Европейской фармакопеи или национальной фармакопеи государства-члена ЕС, когда изменения сделаны исключительно в соответствии с фармакопеей и краткая характеристика особых свойств продукта остается неизменной;
(e) изменения, связанные с изменениями в упаковочном материале, не связанном с готовой продукцией, который не влияет на доставку, использование, безопасность и стабильность лекарственного средства;
(f) изменения, связанные с ужесточением ограничений спецификации, если изменение не является следствием каких-либо заключений из предыдущей оценки по пересмотру ограничений спецификаций и не является результатом непредвиденных событий, возникающих в процессе производства.
2. Следующие изменения должны классифицироваться в качестве основных изменений по типу II:
(a) изменения, связанные с добавлением новых терапевтических свойств или модификацией существующих;
(b) изменения, связанные с существенными изменениями краткой характеристики лекарственного средства, в частности, нового качества, доклинических, клинических выводов или выводов фармаконадзора;
(c) изменения, связанные с изменением вне рамок утвержденных технических условий, ограничений и критериев приемлемости;
(d) изменения, касающиеся существенных изменений в процессе производства, разработки, в технических характеристиках или примесях профиля активного вещества или готового лекарственного средства, которые могут оказать существенное влияние на качество, безопасность и эффективность лекарственного средства;
(e) изменения, связанные с изменениями в процессе производства или элементах активного вещества для биологического лекарственного средства;
(f) изменения, связанные с введением нового дизайна или расширения одобренного, когда дизайн был разработан в соответствии с соответствующими европейскими и международными научными принципами;
(g) изменения, касающиеся изменения или добавления непродовольственных целевых видов;
(h) изменения в отношении замены или дополнения серотипа, штамма, антигена или сочетания серотипов, штаммов или антигенов для ветеринарных вакцин против птичьего гриппа, ящура или катаральной лихорадки овец;
(i) изменения в отношении замены штамма для ветеринарных вакцин против лошадиного гриппа;
(j) изменения, связанные с изменениями в активных веществах сезонного использования, препандемической и пандемической вакцины против человеческого гриппа;
(k) изменения, связанные с изменениями в период после применения ветеринарного лекарственного средства;
(l) изменения в отношении замены или дополнения серотипа, штамма, антигена или кодирующей последовательности или сочетания серотипов, штаммов или антигенов или кодирующих последовательностей для вакцин против коронавируса человека.
ПОЛОЖЕНИЯ
ПО ГРУППИРОВКЕ ИЗМЕНЕНИЙ, УКАЗАННЫХ В СТАТЬЕ 7(2)(b) И СТАТЬЕ 13d(2)(b)
1. Одно из изменений в группе является расширением разрешения на маркетинг.
2. Одно из изменений в группе является значительным изменением по типу II; все остальные изменения в группе являются изменениями, которые являются следствием этих значительных изменений по типу II.
3. Одно из изменений в группе является незначительным изменением по типу IB; все другие изменения в группе имеют незначительные различия, которые являются следствием незначительных изменений по типу IB.
4. Все изменения в группе относятся исключительно к изменениям административного характера кратких характеристик товара, маркировки и упаковки.
5. Все изменения в группе являются изменениями в Главной информации об активном веществе, Главной информации об антигенах вакцины, Главной информации о плазме.
6. Все изменения в группе относятся к проекту, направленному на улучшение производственного процесса и качества лекарственного средства или его активного(-ых) вещества(-в).
7. Все изменения в группе являются изменениями, влияющими на качество вакцины против пандемического гриппа, предназначенной для человека.
8. Все изменения в группе являются изменениями в системе фармаконадзора, перечисленные в пунктах (ia) и (n) Статьи 8(3) Директивы 2001/83/ЕС или пунктах (k) и (o) Статьи 12(3) Директивы 2001/82/ЕС.
9. Все изменения в группе являются следствием применения срочных ограничений в целях безопасности и представлены в соответствии со Статьей 22.
10. Все изменения в группе относятся к реализации данного класса маркировки.
11. Все изменения в группе являются следствием оценки предоставленного периодически обновляемого отчета по безопасности.
12. Все изменения в группе являются следствием проведенного после выдачи разрешения наблюдения, проведенного под контролем владельца.
13. Все изменения в группе являются следствием особых обязательств, осуществляемых в соответствии со Статьей 14(7) Регламента (ЕС) 726/2004.
14. Все изменения в группе являются следствием особой процедуры или условий, осуществляемых в соответствии со Статьями 14(8) или 39(7) Регламента (ЕС) 726/2004, Статьи 22 Директивы 2001/83/ЕС или Статьей 26(3) Директивы 2001/82/ЕС.
1. Все разрешения на маркетинг, указанные в уведомлении или заявлении.
2. Описание всех представленных изменений, в том числе:
(a) в случае незначительных изменений по типу IA — дата осуществления каждого описанного изменения;
(b) в случае незначительных изменений по типу IA, которые не требуют немедленного уведомления, — описание всех незначительных изменений по типу IA, осуществленных в течение последних 12 месяцев в рамках соответствующего(-щих) разрешения(-ий) на маркетинг, и о которых еще не было уведомлений.
3. Все необходимые документы, как указанно в руководящих положениях, упомянутых в пункте (b) Статьи 4(1).
4. Когда изменение приводит к другим изменениям в условия одних и тех же разрешений на маркетинг или является их следствием, — описание связи между этими изменениями.
5. В случае наличия изменений в централизованных разрешениях на маркетинг — соответствующие пошлины, предусмотренные в Регламенте (ЕС) 297/95 <*> Совета ЕС.
<*> ОЖ № L 35, 15.02.1995, стр. 1.
6. В случае наличия изменений к разрешениям на маркетинг, выдаваемым компетентными органами государств-членов ЕС:
(a) список таких государств-членов ЕС с указанием ответственного государства-члена ЕС, если это приемлемо;
(b) соответствующие сборы, предусмотренные действующими национальными правилами в соответствующих государствах-членах ЕС.
Изменения, касающиеся изменения или дополнения показаний к применению.
1. Изменения, касающиеся изменения или добавления непродовольственных целевых видов.
2. Изменения, касающиеся замены или добавления серотипа, штамма, антигена или сочетания серотипов, штаммов или антигенов для ветеринарных вакцин против птичьего гриппа, ящура или катаральной лихорадки овец.
3. Изменения, касающиеся замены штамма для ветеринарных вакцин против лошадиного гриппа.
Федеративная Республика Германия.
COMMISSION REGULATION (EC) No. 1234/2008
CONCERNING THE EXAMINATION OF VARIATIONS TO THE TERMS
OF MARKETING AUTHORISATIONS FOR MEDICINAL PRODUCTS
FOR HUMAN USE AND VETERINARY MEDICINAL PRODUCTS <*>
(Amended by: Commission Regulation (EU)
No 712/2012 of 3 August 2012, Commission Delegated
Regulation (EU) 2021/756 of 24 March 2021)
<*> This text is meant purely as a documentation tool and has no legal effect. The Union's institutions do not assume any liability for its contents. The authentic versions of the relevant acts, including their preambles, are those published in the Official Journal of the European Union and available in EUR-Lex. Those official texts are directly accessible through the links embedded in this document
1. This Regulation lays down provisions concerning the examination of variations to the terms of all marketing authorisations for medicinal products for human use and veterinary medicinal products granted in accordance with Regulation (EC) No 726/2004, Directive 2001/83/EC, Directive 2001/82/EC, and Council Directive 87/22/EEC <*>.
<*> OJ L 15, 17.1.1987, p. 38.
2. This Regulation shall not apply to transfers of a marketing authorisation from one marketing authorisation holder (hereinafter holder) to another.
3. Chapter II shall apply only to variations to the terms of marketing authorisations granted in accordance with Directive 87/22/EEC, Chapter 4 of Directive 2001/82/EC or Chapter 4 of Directive 2001/83/EC.
3a. Chapter IIa shall apply only to variations to the terms of purely national marketing authorisations.
4. Chapter III shall apply only to variations to the terms of marketing authorisations granted in accordance with Regulation (EC) No 726/2004 (hereinafter centralised marketing authorisations).
For the purposes of this Regulation, the following definitions shall apply:
1. «Variation to the terms of a marketing authorisation» or «variation» means any amendment to:
(a) the information referred to in Articles 12(3) to 14 of Directive 2001/82/EC and Annex I thereto, Articles 8(3) to 11 of Directive 2001/83/EC and Annex I thereto, Articles 6(2) and 31(2) of Regulation (EC) No 726/2004, or Article 7 of Regulation (EC) No 1394/2007;
(b) the terms of the decision granting the marketing authorisation for a medicinal product for human use, including the summary of the product characteristics and any conditions, obligations, or restrictions affecting the marketing authorisation, or changes to the labelling or the package leaflet connected with changes to the summary of the product characteristics;
(c) the terms of the decision granting the marketing authorisation for a veterinary medicinal product, including the summary of the product characteristics and any conditions, obligations, or restrictions affecting the marketing authorisation, or changes to the labelling or the package leaflet;
2. «Minor variation of type IA» means a variation which has only a minimal impact, or no impact at all, on the quality, safety or efficacy of the medicinal product concerned;
3. «Major variation of type II» means a variation which is not an extension and which may have a significant impact on the quality, safety or efficacy of the medicinal product concerned;
4. «Extension of a marketing authorisation» or «extension» means a variation which is listed in Annex I and fulfils the conditions laid down therein;
5. «Minor variation of type IB» means a variation which is neither a minor variation of type IA nor a major variation of type II nor an extension;
6. «Member State concerned» means a Member State whose competent authority has granted a marketing authorisation for the medicinal product in question;
7. «Relevant authority» means:
(a) the competent authority of each Member State concerned;
(b) in the case of centralised marketing authorisations, the Agency;
8. «Urgent safety restriction» means an interim change in the terms of the marketing authorisation due to new information having a bearing on the safe use of the medicinal product;
9. «Purely national marketing authorisation» means any marketing authorisation granted by a Member State in accordance with the acquis outside the mutual recognition or decentralised procedure and that has not been subject to a complete harmonisation following a referral procedure.
1. In relation to any variation which is not an extension the classification laid down in Annex II shall apply.
2. A variation which is not an extension and whose classification is undetermined after application of the rules provided for in this Regulation, taking into account the guidelines referred to in Article 4(1) and, where relevant, any recommendations delivered pursuant to Article 5, shall by default be considered a minor variation of type IB.
3. By way of derogation from paragraph 2, a variation which is not an extension and whose classification is undetermined after application of the rules provided for in this Regulation shall be considered a major variation of type II in the following cases:
(a) upon request from the holder when submitting the variation;
(b) where the competent authority of the reference Member State as referred to in Article 32 of Directive 2001/82/EC and Article 28 of Directive 2001/83/EC (hereinafter «the reference Member State»), in consultation with the other Member States concerned, or the Agency in the case of a centralised marketing authorisation, or the competent authority in the case of a purely national marketing authorisation, concludes, following the assessment of validity of a notification in accordance with Article 9(1), Article 13b(1), or Article 15(1) and taking into account the recommendations delivered pursuant to Article 5, that the variation may have a significant impact on the quality, safety or efficacy of the medicinal product concerned.
1. The Commission shall, after consulting the Member States and the Agency, draw up guidelines on the details of the various categories of variations, on the operation of the procedures laid down in Chapters II, IIa, III and IV of this Regulation, and on the documentation to be submitted pursuant to those procedures.
1. Prior to the submission of a variation whose classification is not provided for in this Regulation, a holder may request a recommendation on the classification of the variation as follows:
(a) to the Agency, where the variation refers to a marketing authorisation granted under Regulation (EC) No 726/2004;
(b) to the competent authority of the Member State concerned, where the variation refers to a purely national marketing authorisation;
(c) to the competent authority of the reference Member State, in the other cases.
The recommendation referred to in the first subparagraph shall be consistent with the guidelines referred to in Article 4(1). It shall be delivered within 45 days following receipt of the request and sent to the holder, the Agency, and the coordination group referred to in Article 31 of Directive 2001/82/EC or in Article 27 of Directive 2001/83/EC.
The 45-day period referred to in the second subparagraph may be extended by 25 days where the relevant authority deems it necessary to consult with the coordination group.
1a. Prior to the examination of a variation whose classification is not provided for in this Regulation, a competent authority of a Member State may request a recommendation on the classification of the variation to the coordination group.
The recommendation referred to in the first subparagraph shall be consistent with the guidelines referred to in Article 4(1). It shall be delivered within 45 days following receipt of the request and sent to the holder, the Agency, and the competent authorities of all Member States.
2. The Agency and the two coordination groups referred to in paragraph 1 shall cooperate to ensure the coherence of the recommendations delivered in accordance with that paragraph and publish those recommendations after deletion of all information of commercial confidential nature.
Variations leading to the revision of product information
Where a variation leads to the revision of the summary of product characteristics, labelling or package leaflet, this revision shall be considered as part of that variation.
1. Where several variations are notified or applied for, a separate notification or application in accordance with Chapters II, III, or Article 19 as appropriate shall be submitted in respect of each variation sought.
2. By way of derogation from paragraph 1, the following shall apply:
(a) where the same minor variation(s) of type IA to the terms of one or more marketing authorisations owned by the same holder are notified at the same time to the same relevant authority, a single notification as referred to in Article 8 or 14 may cover all such variations;
(b) where several variations to the terms of the same marketing authorisation are submitted at the same time, a single submission may cover all such variations provided that the variations concerned fall within one of the cases listed in Annex III;
(c) where several variations to the terms of the same marketing authorisation are submitted at the same time and the variations do not fall within one of the cases listed in Annex III, a single submission may cover all such variations provided that the competent authority of the reference Member State in consultation with the competent authorities of the Member States concerned or, in the case of a centralised marketing authorisation, the Agency agrees to such single submission.
The submission referred to in subparagraphs (b) and (c) shall be made simultaneously to all relevant authorities by means of the following:
(i) a single notification in accordance with Article 9 or 15 where at least one of the variations is a minor variation of type IB and the remaining variations are minor variations;
(ii) a single application in accordance with Article 10 or 16 where at least one of the variations is a major variation of type II and none of the variations is an extension;
(iii) a single application in accordance with Article 19 where at least one of the variations is an extension.
1. Where a minor variation of type IA is made, the holder shall submit simultaneously to all relevant authorities a notification containing the elements listed in Annex IV. This notification shall be submitted within 12 months following the implementation of the variation.
However, the notification shall be submitted immediately after the implementation of the variation in the case of minor variations requiring immediate notification for the continuous supervision of the medicinal product concerned.
2. Within 30 days following receipt of the notification, the measures provided for in Article 11 shall be taken.
1. The holder shall submit simultaneously to all relevant authorities a notification containing the elements listed in Annex IV.
If the notification fulfils the requirement laid down in the first subparagraph, the competent authority of the reference Member State shall, after consulting the other Member States concerned, acknowledge receipt of a valid notification.
2. If within 30 days following the acknowledgement of receipt of a valid notification, the competent authority of the reference Member State has not sent the holder an unfavourable opinion, the notification shall be deemed accepted by all relevant authorities.
Where the notification is accepted by the competent authority of the reference Member State, the measures provided for in Article 11 shall be taken.
3. Where the competent authority of the reference Member State is of the opinion that the notification cannot be accepted, it shall inform the holder and the other relevant authorities, stating the grounds on which its unfavourable opinion is based.
Within 30 days following the receipt of the unfavourable opinion, the holder may submit to all relevant authorities an amended notification in order to take due account of the grounds laid down in that opinion.
If the holder does not amend the notification in accordance with the second subparagraph, the notification shall be deemed rejected by all relevant authorities and the measures provided for in Article 11 shall be taken.
4. Where an amended notification has been submitted, the competent authority of the reference Member State shall assess it within 30 days following its receipt and the measures provided for in Article 11 shall be taken.
5. This Article shall not apply where a type IB variation request is submitted in a grouping that includes a variation type II and does not contain an extension. In such case, the prior approval procedure in Article 10 shall apply.
This Article shall not apply where a type IB variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. The holder shall submit simultaneously to all relevant authorities an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the competent authority of the reference Member State shall acknowledge receipt of a valid application and inform the holder and the other relevant authorities that the procedure starts from the date of such acknowledgement.
2. Within 60 days following the acknowledgement of receipt of a valid application, the competent authority of the reference Member State shall prepare an assessment report and a decision on the application, which shall be communicated to the other relevant authorities.
The competent authority of the reference Member State may reduce the period referred to in the first subparagraph, having regard to the urgency of the matter, or extend it to 90 days for variations listed in Part 1 of Annex V or for grouping of variations in accordance with Article 7(2)(c).
The period referred to in the first subparagraph shall be 90 days for variations listed in Part 2 of Annex V.
3. Within the period referred to in paragraph 2, the competent authority of the reference Member State may request the holder to provide supplementary information within a time limit set by that competent authority. In this case:
(a) the competent authority of the reference Member State shall inform the other competent authorities concerned of its request for supplementary information;
(b) the procedure shall be suspended until such supplementary information has been provided;
(c) the competent authority of the reference Member State may extend the period referred to in paragraph 2.
4. Without prejudice to Article 13 and within 30 days following receipt of the decision and of the assessment report referred to in paragraph 2, the relevant authorities shall recognise the decision and inform the competent authority of the reference Member State accordingly.
If, within the period referred to in the first subparagraph, a relevant authority has not expressed its disagreement in accordance with Article 13, the decision shall be deemed recognised by that relevant authority.
5. Where the decision referred to in paragraph 2 has been recognised by all relevant authorities in accordance with paragraph 4, the measures provided for in Article 11 shall be taken.
6. This Article shall not apply where a type II variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. Where reference is made to this Article, the competent authority of the reference Member State shall take the following measures:
(a) it shall inform the holder and the other relevant authorities as to whether the variation is accepted or rejected;
(b) where the variation is rejected, it shall inform the holder and the other relevant authorities of the grounds for the rejection;
(c) it shall inform the holder and the other relevant authorities as to whether the variation requires any amendment to the decision granting the marketing authorisation.
2. Where reference is made to this Article, each relevant authority shall, where necessary and within the time limit laid down in paragraph 1 of Article 23, amend the decision granting the marketing authorisation in accordance with the accepted variation.
1. By way of derogation from Article 10, the procedure laid down in paragraphs 2 to 5 shall apply to the examination of variations concerning changes to the active substance for the purposes of the annual update of a human influenza vaccine.
2. The holder shall submit simultaneously to all relevant authorities an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the competent authority of the reference Member State shall acknowledge receipt of a valid application and inform the holder and the other relevant authorities that the procedure starts from the date of such acknowledgement.
3. The competent authority of the reference Member State shall assess the application submitted. Where deemed necessary, the competent authority of the reference Member State may request additional data to the holder in order to complete its assessment.
4. The competent authority shall prepare a decision and an assessment report within 45 days from the receipt of a valid application.
The 45-day period referred to in the first subparagraph shall be suspended from the moment when the additional data referred to in paragraph 3 is requested until the data is submitted.
5. Within 12 days from the receipt of the decision and the assessment report of the competent authority of the reference Member State, the relevant authorities shall adopt a decision accordingly and inform the competent authority of the reference Member State and the holder thereof.
1. Where recognition of a decision in accordance with Article 10(4) or approval of an opinion in accordance with point (b) of Article 20(8) is not possible on grounds of a potential serious risk to public health in the case of medicinal products for human use or, in the case of veterinary medicinal products, on grounds of a potential serious risk to human or animal health or to the environment, a relevant authority shall request that the matter of disagreement be forthwith referred to the coordination group.
The party in disagreement shall give a detailed statement of the reasons for its position to all Member States concerned and to the applicant.
2. Article 33(3), (4) and (5) of Directive 2001/82/EC or Article 29(3), (4) and (5) of Directive 2001/83/EC shall apply to the matter of disagreement referred to in paragraph 1.
1. Where a minor variation of type IA is made, the holder shall submit to the competent authority a notification containing the elements listed in Annex IV. This notification shall be submitted within 12 months following the implementation of the variation.
However, the notification shall be submitted immediately after the implementation of the variation in the case of minor variations requiring immediate notification for the continuous supervision of the medicinal product concerned.
2. Within 30 days following receipt of the notification, the measures provided for in Article 13e shall be taken.
1. The holder shall submit to the competent authority a notification containing the elements listed in Annex IV.
If the notification fulfils the requirement laid down in the first subparagraph, the competent authority shall acknowledge receipt of a valid notification.
2. If within 30 days following the acknowledgement of receipt of a valid notification, the competent authority has not sent the holder an unfavourable opinion, the notification shall be deemed accepted by the competent authority.
Where the notification is accepted by the competent authority, the measures provided for in Article 13e shall be taken.
3. Where the competent authority is of the opinion that the notification cannot be accepted, it shall inform the holder, stating the grounds on which its unfavourable opinion is based.
Within 30 days following the receipt of the unfavourable opinion, the holder may submit to the competent authority an amended notification in order to take due account of the grounds laid down in that opinion.
If the holder does not amend the notification in accordance with the second subparagraph, the notification shall be deemed rejected.
4. Where an amended notification has been submitted, the competent authority shall assess it within 30 days following its receipt and the measures provided for in Article 13e shall be taken.
5. This Article shall not apply where a type IB variation request is submitted in a grouping that includes a variation type II and does not contain an extension. In such case, the prior approval procedure in Article 13c shall apply.
This Article shall not apply where a type IB variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. The holder shall submit to the competent authority an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the competent authority shall acknowledge receipt of a valid application.
2. Within 60 days following the acknowledgement of receipt of a valid application, the competent authority shall conclude the assessment.
The competent authority may reduce the period referred to in the first subparagraph, having regard to the urgency of the matter, or extend it to 90 days for variations listed in Part 1 of Annex V or for grouping of variations in accordance with Article 13d(2)(c).
The period referred to in the first subparagraph shall be 90 days for variations listed in Part 2 of Annex V.
3. Within the periods referred to in paragraph 2, the competent authority may request the holder to provide supplementary information within a time limit set by the competent authority. In this case the procedure shall be suspended until such supplementary information has been provided and the competent authority may extend the period referred to in paragraph 2.
4. Within 30 days after the conclusion of the assessment, the measures provided for in Article 13e shall be taken.
5. This Article shall not apply where a type II variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. Where several variations are notified or applied for, a separate notification or application in accordance with Articles 13a, 13b, 13c, or 19 as appropriate shall be submitted to the competent authority in respect of each variation sought.
2. By way of derogation from paragraph 1 the following shall apply:
(a) where the same minor variation(s) of type IA to the terms of one or more marketing authorisations owned by the same holder are notified at the same time to the same competent authority, a single notification as referred to in Article 13a may cover all such variations;
(b) where several variations to the terms of the same marketing authorisation are submitted at the same time to the same competent authority, a single submission may cover all such variations provided that the variations concerned fall within one of the cases listed in Annex III;
(c) where the same variation(s) to the terms of one or more marketing authorisations owned by the same holder are submitted at the same time to the same competent authority and they are not covered under subparagraph (a) or (b), a single submission may cover all such variations provided that the competent authority agrees to such single submission.
The submission referred to in points (b) and (c) shall be made by means of the following:
(i) a single notification in accordance with Article 13b where at least one of the variations is a minor variation of type IB and the remaining variations are minor variations;
(ii) a single application in accordance with Article 13c where at least one of the variations is a major variation of type II and none of the variations is an extension;
(iii) a single application in accordance with Article 19 where at least one of the variations is an extension.
Where reference is made to this Article, the competent authority shall take the following measures:
(a) it shall inform the holder as to whether the variation is accepted or rejected;
(b) where the variation is rejected, it shall inform the holder of the grounds for the rejection;
(c) where necessary, it shall amend the decision granting the marketing authorisation in accordance with the accepted variation within the time limit laid down in paragraph 1 of Article 23.
1. By way of derogation from Article 13c, the procedure laid down in paragraphs 2 to 4 shall apply to the examination of variations concerning changes to the active substance for the purposes of the annual update of a human influenza vaccine.
2. The holder shall submit to the competent authority an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the competent authority shall acknowledge receipt of a valid application.
3. The competent authority shall assess the application submitted. Where deemed necessary, the competent authority may request additional data to the holder in order to complete its assessment.
4. The competent authority shall adopt a decision within 45 days from the receipt of a valid application and shall take the measures provided for in Article 13e.
The 45-day period referred to in the first subparagraph shall be suspended from the moment when the additional data referred to in paragraph 3 is requested until the data is submitted.
1. Where a minor variation of type IA is made, the holder shall submit to the Agency a notification containing the elements listed in Annex IV. This notification shall be submitted within 12 months following implementation of the variation.
However, the notification shall be submitted immediately after the implementation of the variation in the case of minor variations requiring immediate notification for the continuous supervision of the medicinal product concerned.
2. Within 30 days following receipt of the notification, the measures provided for in Article 17 shall be taken.
1. The holder shall submit to the Agency a notification containing the elements listed in Annex IV.
If the notification fulfils the requirement laid down in the first subparagraph, the Agency shall acknowledge receipt of a valid notification.
2. If within 30 days following the acknowledgement of receipt of a valid notification the Agency has not sent the holder an unfavourable opinion, its opinion shall be deemed favourable.
Where the opinion of the Agency on the notification is favourable, the measures provided for in Article 17 shall be taken.
3. Where the Agency is of the opinion that the notification cannot be accepted, it shall inform the holder, stating the grounds on which its unfavourable opinion is based.
Within 30 days of receipt of the unfavourable opinion, the holder may submit to the Agency an amended notification in order to take due account of the grounds laid down in that opinion.
If the holder does not amend the notification in accordance with the second subparagraph, the notification shall be deemed rejected.
4. Where an amended notification has been submitted, the Agency shall assess it within 30 days following its receipt and the measures provided for in Article 17 shall be taken.
5. This Article shall not apply where a type IB variation request is submitted in a grouping that includes a variation type II and does not contain an extension. In such case, the prior approval procedure in Article 16 shall apply.
This Article shall not apply where a type IB variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. The holder shall submit to the Agency an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the Agency shall acknowledge receipt of a valid application.
2. The Agency shall issue an opinion on the valid application referred to in paragraph 1 within 60 days following its receipt.
The Agency may reduce the period referred to in the first subparagraph, having regard to the urgency of the matter, or extend it to 90 days for variations listed in Part 1 of Annex V or for grouping of variations in accordance with Article 7(2)(c).
The period referred to in the first subparagraph shall be 90 days for variations listed in Part 2 of Annex V.
3. Within the period referred to in paragraph 2, the Agency may request the holder to provide supplementary information within a time limit set by the Agency. The procedure shall be suspended until such time as the supplementary information has been provided. In this case the Agency may extend the period referred to in paragraph 2.
4. Article 9(1) and (2) and Article 34(1) and (2) of Regulation (EC) No 726/2004 shall apply to the opinion on the valid application.
Within 15 days from the adoption of the final opinion on the valid application, the measures provided for in Article 17 shall be taken.
5. This Article shall not apply where a type II variation request is submitted in a grouping that includes an extension. In such case, the procedure in Article 19 shall apply.
1. Where reference is made to this Article, the Agency shall take the following measures:
(a) it shall inform the holder of the outcome of the assessment;
(b) where the variation is rejected, it shall inform the holder of the grounds for the rejection;
(c) where the outcome of the assessment is favourable and the variation affects the terms of the Commission decision granting the marketing authorisation, the Agency shall transmit to the Commission its opinion and the grounds for its opinion as well as the revised versions of the documents referred to in Article 9(4) or Article 34(4) of Regulation (EC) No 726/2004 as appropriate.
2. In the cases identified under paragraph 1(c), the Commission, having regard to the opinion from the Agency and within the time limit foreseen in Article 23(1a), shall amend where necessary the decision granting the marketing authorisation. The Community Register of Medicinal Products provided for in Article 13(1) and Article 38(1) of Regulation (EC) No 726/2004 shall be updated accordingly.
1. By way of derogation from Article 16, the procedure laid down in paragraphs 2 to 6 shall apply to the examination of variations concerning changes to the active substance for the purposes of the annual update of a human influenza vaccine.
2. The holder shall submit to the Agency an application containing the elements listed in Annex IV.
If the application fulfils the requirements laid down in the first subparagraph, the Agency shall acknowledge receipt of a valid application and inform the holder that the procedure starts from the date of such acknowledgement.
3. The Agency shall assess the application submitted. Where deemed necessary, the Agency may request additional data to complete its assessment.
4. Within 55 days from the receipt of a valid application, the Agency shall adopt an opinion. The Agency's opinion on the application shall be transmitted to the applicant. Where the Agency's opinion is favourable, the Agency shall also transmit to the Commission its opinion and the grounds for its opinion as well as the revised versions of the documents referred in Article 9(4) of Regulation (EC) No 726/2004.
5. The 55-day period referred to in paragraph 4 shall be suspended from the moment when the additional data referred to in paragraph 3 is requested until the data is submitted.
6. Having regard to the favourable opinion of the Agency, the Commission shall amend where necessary the decision granting the marketing authorisation. The Community Register of Medicinal Products provided for in Article 13(1) of Regulation (EC) No 726/2004 shall be updated accordingly.
1. An application for an extension of a marketing authorisation shall be evaluated in accordance with the same procedure as for the initial marketing authorisation to which it relates.
2. An extension shall either be granted a marketing authorisation in accordance with the same procedure as for the granting of the initial marketing authorisation to which it relates or be included in that marketing authorisation.
1. By way of derogation from Articles 7(1), 9, 10, 13b, 13c, 13d, 15 and 16the holder of a marketing authorisation may choose to follow the worksharing procedure laid down in paragraphs 3 to 9 in the following cases:
(a) for marketing authorisations referred to in Chapters II and III, where a minor variation of type IB, a major variation of type II, or a group of variations as provided for in Article 7(2)(b) or (c) that does not contain any extension relates to several marketing authorisations owned by the same holder;
(b) for purely national marketing authorisations referred to in Chapter IIa, where a minor variation of type IB, a major variation of type II, or a group of variations as provided for in Article 13d(2)(b) or (c) that does not contain any extension relates to several marketing authorisations owned by the same holder;
(c) for purely national marketing authorisations referred to in Chapter IIa, where a minor variation of type IB, a major variation of type II, or a group of variations as provided for in Article 13d(2)(b) or (c) that does not contain any extension relates to one marketing authorisation that is owned by the same holder in more than one Member State.
Variations covered under (a), (b) or (c) may be subject to the same worksharing procedure.
The reference authority or, in the case of purely national marketing authorisations, the competent authority may refuse to process a submission under the worksharing procedure where the same change(s) to different marketing authorisations require the submission of individual supportive data for each medicinal product concerned or a separate product-specific assessment.
2. For the purposes of this Article, «reference authority» shall mean one of the following:
(a) the Agency where at least one of the marketing authorisations referred to in paragraph 1 is a centralised marketing authorisation;
(b) the competent authority of a Member State concerned chosen by the coordination group, taking into account a recommendation of the holder, in the other cases.
3. The holder shall submit to all relevant authorities an application containing the elements listed in Annex IV, with an indication of the recommended reference authority.
The coordination group shall choose a reference authority. If the application fulfils the requirements laid down in the first subparagraph, that reference authority shall acknowledge receipt of a valid application.
Where the chosen reference authority is the competent authority of a Member State which has not granted a marketing authorisation for all the medicinal products affected by the application, the coordination group may request another relevant authority to assist the reference authority in the evaluation of that application.
4. The reference authority shall issue an opinion on the valid application referred to in paragraph 3 within one of the following periods:
(a) a period of 60 days following acknowledgement of receipt of a valid application in the case of minor variations of type IB or major variations of type II;
(b) a period of 90 days following acknowledgement of receipt of a valid application in the case of variations listed in Part 2 of Annex V.
5. The reference authority may reduce the period referred to in point (a) of paragraph 4, having regard to the urgency of the matter, or extend it to 90 days for variations listed in Part 1 of Annex V or for grouping of variations in accordance with Article 7(2)(c) or Article 13d(2)(c).
6. Within the period referred to in paragraph 4, the reference authority may request the holder to provide supplementary information within a time limit set by the reference authority. In this case:
(a) the reference authority shall inform the other relevant authorities of its request for supplementary information;
(b) the procedure shall be suspended until such supplementary information has been provided;
(c) the reference authority may extend the period referred to in point (a) of paragraph 4.
7. Where the reference authority is the Agency, Article 9(1) and (2)and Article 34(1) and (2) of Regulation (EC) No 726/2004 shall apply to the opinion referred to in paragraph 4.
The Agency's opinion on the application shall be transmitted to the applicant and the Member States, together with the assessment report. Where the outcome of the assessment is favourable and the variation affects the terms of the Commission decision granting the marketing authorisation, the Agency shall also transmit to the Commission its opinion and the grounds for its opinion as well as the revised versions of the documents referred in Article 9(4) of Regulation (EC) No 726/2004.
Where the Agency issues a favourable opinion, the following shall apply:
(a) if the opinion recommends the variation to the terms of a Commission decision granting the marketing authorisation, the Commission shall, having regard to the final opinion and within the time limits foreseen in Article 23(1a), amend the decision(s) accordingly, provided that the revised versions of the documents referred to in Article 9(4) or Article 34(4) of Regulation (EC) No 726/2004 have been received. The Community Register of Medicinal Products provided for in Article 13(1) and Article 38(1) of Regulation (EC) No 726/2004 shall be updated accordingly;
(b) the Member States concerned shall, within 60 days following receipt of the final opinion of the Agency, approve that final opinion, inform the Agency thereof and, where necessary, amend the marketing authorisations concerned accordingly, provided that the documents necessary for the amendment of the marketing authorisation have been transmitted to the Member States concerned.
8. Where the reference authority is the competent authority of a Member State:
(a) it shall send its opinion on the valid application to the holder and to all relevant authorities;
(b) without prejudice to Article 13 and within 30 days following receipt of the opinion, the relevant authorities shall approve that opinion and inform the reference authority;
(c) the concerned marketing authorisations shall be amended accordingly within 30 days following the approval of the opinion, provided that the documents necessary for the amendment of the marketing authorisation have been transmitted to the Member States concerned.
9. Upon request from the reference authority, the Member States concerned shall provide information related to the marketing authorisations affected by the variation for the purpose of verifying the validity of the application and of issuing the opinion on the valid application.
10. Where harmonisation of a section of the summary of product characteristics of a purely national marketing authorisation has been achieved through a worksharing procedure, any subsequent variation submission affecting the harmonised section shall be transmitted simultaneously to all Member States concerned.
(1) By way of derogation from Chapters I, II, IIa and III, where a pandemic situation with respect to human influenza or human coronavirus is duly recognised by the World Health Organization or by the Union in the framework of Decision No 1082/2013/EU of the European Parliament and of the Council <*>, the relevant authorities, or in the case of centralised marketing authorisations, the Commission may, where certain pharmaceutical, non-clinical or clinical data are missing, exceptionally and temporarily accept a variation to the terms of a marketing authorisation for a human influenza vaccine or a human coronavirus vaccine.
<*> Decision No 1082/2013/EU of the European Parliament and of the Council of 22 October 2013 on serious cross-border threats to health and repealing Decision No 2119/98/EC (OJ L 293, 5.11.2013, p. 1).
(2) The relevant authority may request the applicant to provide supplementary information in order to complete its assessment within a time limit set by it.
(3) Variations may be accepted pursuant to paragraph 1 only if the benefit-risk balance of the medicinal product is favourable.
(4) Where a variation is accepted pursuant to paragraph 1, the holder shall submit the missing pharmaceutical, non-clinical and clinical data within a time limit set by the relevant authority.
(5) In the case of centralised marketing authorisations, the missing data and the time limit for submission or compliance shall be specified in the conditions to the marketing authorisation. Where the marketing authorisation has been granted in accordance with Article 14-a of Regulation (EC) No 726/2004 this may be done as part of the specific obligations referred to in paragraph 4 of that Article.
1. Where, in the event of a risk to public health in the case of medicinal products for human use or, in the case of veterinary medicinal products, in the event of a risk to human or animal health or to the environment, the holder takes urgent safety restrictions on its own initiative, it shall forthwith inform all relevant authorities and, in the case of a centralised marketing authorisation, the Agency.
If the relevant authority or, in the case of a centralised marketing authorisation, the Agency has not raised objections within 24 hours following receipt of that information, the urgent safety restrictions shall be deemed accepted.
2. In the event of a risk to public health in the case of medicinal products for human use or, in the case of veterinary medicinal products, in the event of a risk to human or animal health or to the environment, relevant authorities or, in the case of centralised marketing authorisations, the Commission may impose urgent safety restrictions on the holder.
3. Where an urgent safety restriction is taken by the holder or imposed by a relevant authority or the Commission, the holder shall submit the corresponding application for variation within 15 days following the initiation of that restriction.
1. Amendments to the decision granting the marketing authorisation resulting from the procedures laid down in Chapters II and IIa shall be made:
(a) in the case of major variations of type II, within two months following receipt of the information referred to in Article 11(1)(c) and Article 13e(a), provided that the documents necessary for the amendment of the marketing authorisation have been transmitted to the Member States concerned;
(b) in the other cases, within six months following receipt of the information referred to in Article 11(1)(c) and Article 13e(a), provided that the documents necessary for the amendment of the marketing authorisation have been transmi tted to the Member States concerned.
1a. Amendments to the decision granting the marketing authorisation resulting from the procedures laid down in Chapter III shall be made:
(a) within two months following receipt of the information referred to in Article 17(1)(c) for the following variations:
(i) variations related to the addition of a new therapeutic indication or to the modification of an existing one;
(ii) variations related to the addition of a new contraindication;
(iii) variations related to a change in posology;
(iv) variations related to the addition of a non-food producing target species or the modification of an existing one for veterinary medicinal products;
(v) variations concerning the replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine;
(vi) variations related to changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza;
(vii) variations related to changes to the withdrawal period for a veterinary medicinal product;
(viii) other type II variations that are intended to implement changes to the decision granting the marketing authorisation due to a significant public health concern or significant animal health or environmental concern in the case of veterinary medicinal products;
(ix) variations related to changes to the active substance of a human coronavirus vaccine, including replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences;
(b) within 12 months following receipt of the information referred to in Article 17(1)(c) in the other cases.
The Agency shall determine the variations referred to in point (a)(viii) and provide reasons for such determination.
2. Where the decision granting a marketing authorisation is amended as a result of one of the procedures laid down in Chapters II, III and IV, the relevant authority or, in the case of centralised marketing authorisations, the Commission shall notify the amended decision without delay to the holder.
Article 23a
The statement indicating compliance with the agreed completed paediatric investigation plan provided for under Article 28(3) of Regulation (EC) No 1901/2006 shall be included within the technical dossier of the marketing authorisation.
The relevant authority shall provide the holder with a confirmation that the statement is included in the technical dossier within 30 days after the relevant assessment has been concluded.
1. Minor variations of type IA may be implemented any time before completion of the procedures laid down in Articles 8, 13a and 14.
Where a notification concerning one or several minor variations of type IA is rejected, the holder shall cease to apply the concerned variation(s) immediately after receipt of the information referred to in Articles 11(1)(a), 13e(a), and 17(1)(a).
2. Minor variations of type IB may only be implemented in the following cases:
(a) for variations submitted in accordance with the procedures laid down in Chapter II, after the competent authority of the reference Member State has informed the holder that it has accepted the notification pursuant to Article 9, or after the notification is deemed accepted pursuant to Article 9(2);
(b) for variations submitted in accordance with the procedures laid down in Chapter IIa, after the relevant authority has informed the holder that it has accepted the notification pursuant to Article 13b, or after the notification is deemed accepted pursuant to Article 13b(2);
(c) for variations submitted in accordance with the procedures laid down in Chapter III, after the Agency has informed the holder that its opinion referred to in Article 15 is favourable, or after that opinion is deemed favourable pursuant to Article 15(2);
(d) for variations submitted in accordance with the procedure laid down in Article 20, after the reference authority has informed the holder that its opinion is favourable.
3. Major variations of type II may only be implemented in the following cases:
(a) for variations submitted in accordance with the procedures laid down in Chapter II, 30 days after the competent authority of the reference Member State has informed the holder that it has accepted the variation pursuant to Article 10, under the condition that the documents necessary for the amendment to the marketing authorisation have been provided to the Member States concerned. Where an arbitration procedure has been initiated in accordance with Article 13, the holder shall not implement the variation until the arbitration procedure has concluded that the variation is accepted;
(b) for variations submitted in accordance with the procedures laid down in Chapter IIa, after the competent authority has informed the holder that it has accepted the variation pursuant to Article 13c;
(c) for variations submitted in accordance with the procedures laid down in Chapter III, after the Agency has informed the holder that its opinion referred to in Article 16 is favourable, unless the variation is one referred to in Article 23(1a)(a).
Variations referred to in Article 23(1a)(a) may only be implemented after the Commission has amended the decision granting the marketing authorisation and notified the holder thereof;
(d) for variations submitted in accordance with the procedure laid down in Article 20, 30 days after the reference authority has informed the holder that its opinion is favourable, under the condition that the documents necessary for the amendment to the marketing authorisation have been provided to the Member States concerned; unless an arbitration procedure has been initiated in accordance with Article 13, or unless the procedure concerns a variation to a centralised marketing authorisation as referred to in Article 23(1a)(a).
Where an arbitration procedure has been initiated in accordance with Article 13, or where the worksharing procedure concerns a variation to a centralised marketing authorisation as referred to in Article 23(1a)(a), the holder shall not implement the variation until the arbitration procedure has concluded that the variation is accepted, or until the Commission Decision amending the decision granting the marketing authorisation has been adopted.
4. An extension may only be implemented after the relevant authority or, in the case of extensions to a centralised marketing authorisation, the Commission has amended the decision granting the marketing authorisation and notified the holder accordingly.
5. Urgent safety restrictions and variations which are related to safety issues shall be implemented within a time frame agreed by the holder and the relevant authority and, in the case of a centralised marketing authorisation, the Agency.
By way of derogation from the first subparagraph, urgent safety restrictions and variations related to safety issues which concern marketing authorisations granted in accordance with Chapter 4 of Directive 2001/82/EC or Chapter 4 of Directive 2001/83/EC shall be implemented within a time frame agreed by the holder and the competent authority of the reference Member State, in consultation with the other relevant authorities.
Member States that, in accordance with Article 23b(4) of Directive 2001/83/EC, may continue to apply their national provisions on variations to certain purely national marketing authorisations are listed in Annex VI to this Regulation.
Where requested by a relevant authority, the holder shall supply without delay any information related to the implementation of a given variation.
By two years from the date referred to in the second subparagraph of Article 28, the Commission services shall assess the application of this Regulation as regards the classification of variations, with a view to proposing any necessary amendments to adapt Annexes I, II and V to take account of scientific and technical progress.
1. Regulations (EC) No 1084/2003 and (EC) No 1085/2003 are hereby repealed.
References to the repealed Regulations shall be construed as references to this Regulation.
2. By way of derogation from paragraph 1, Regulations (EC) Nos 1084/2003 and 1085/2003 shall continue to apply to valid notifications or applications for variations which are pending at the date referred to in the second subparagraph of Article 28.
This Regulation shall enter into force on the 20th day following its publication in the Official Journal of the European Union.
It shall apply from 1 January 2010.
By way of derogation from the second subparagraph, the recommendations on unforeseen variations provided for in Article 5 may be requested, delivered and published from the date of entry into force referred to in the first subparagraph.
This Regulation shall be binding in its entirety and directly applicable in all Member States.
1. Changes to the active substance(s):
(a) replacement of a chemical active substance by a different salt/ester complex/derivative, with the same therapeutic moiety, where the efficacy/safety characteristics are not significantly different;
(b) replacement by a different isomer, a different mixture of isomers, of a mixture by an isolated isomer (e.g. racemate by a single enantiomer), where the efficacy/safety characteristics are not significantly different;
(c) replacement of a biological active substance with one of a slightly different molecular structure where the efficacy and/or safety characteristics are not significantly different, with the exception of:
- changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza;
- replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine;
- replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue;
- replacement of a strain for a veterinary vaccine against equine influenza;
(d) modification of the vector used to produce the antigen or the source material, including a new master cell bank from a different source, where the efficacy/safety characteristics are not significantly different;
(e) a new ligand or coupling mechanism for a radiopharmaceutical, where the efficacy/safety characteristics are not significantly different;
(f) change to the extraction solvent or the ratio of herbal drug to herbal drug preparation where the efficacy/safety characteristics are not significantly different.
2. Changes to strength, pharmaceutical form and route of administration:
(a) change of bioavailability;
(b) change of pharmacokinetics e.g. change in rate of release;
(c) change or addition of a new strength/potency;
(d) change or addition of a new pharmaceutical form;
(e) change or addition of a new route of administration <*>.
<*> For parenteral administration, it is necessary to distinguish between intra-arterial, intravenous, intramuscular, subcutaneous and other routes. For administration to poultry, respiratory, oral and ocular (nebulisation) routes used for vaccination are considered to be equivalent routes of administration.
3. Other changes specific to veterinary medicinal products to be administered to food-producing animals: change or addition of target species.
1. The following variations shall be classified as minor variations of type IA:
(a) variations of purely administrative nature that are related to the identity and contact details of:
- the holder;
- the manufacturer or supplier of any starting material, reagent, intermediate, active substance used in the manufacturing process or finished product;
(b) variations related to the deletion of any manufacturing site, including for an active substance, intermediate or finished product, packaging site, manufacturer responsible for batch release, site where batch control takes place;
(c) variations related to minor changes to an approved physico-chemical test procedure, where the updated procedure is demonstrated to be at least equivalent to the former test procedure, appropriate validation studies have been performed and the results show that the updated test procedure is at least equivalent to the former;
(d) variations related to changes made to the specifications of the active substance or of an excipient in order to comply with an update of the relevant monograph of the European Pharmacopoeia or of the national pharmacopoeia of a Member State, where the change is made exclusively to comply with the pharmacopoeia and the specifications for product specific properties are unchanged;
(e) variations related to changes in the packaging material not in contact with the finished product, which do not affect the delivery, use, safety or stability of the medicinal product;
(f) variations related to the tightening of specification limits, where the change is not a consequence of any commitment from previous assessment to review specification limits and does not result from unexpected events arising during manufacture.
2. The following variations shall be classified as major variations of type II:
(a) variations related to the addition of a new therapeutic indication or to the modification of an existing one;
(b) variations related to significant modifications of the summary of product characteristics due in particular to new quality, pre-clinical, clinical or pharmacovigilance findings;
(c) variations related to changes outside the range of approved specifications, limits or acceptance criteria;
(d) variations related to substantial changes to the manufacturing process, formulation, specifications or impurity profile of the active substance or finished medicinal product which may have a significant impact on the quality, safety or efficacy of the medicinal product;
(e) variations related to modifications in the manufacturing process or sites of the active substance for a biological medicinal product;
(f) variations related to the introduction of a new design space or the extension of an approved one, where the design space has been developed in accordance with the relevant European and international scientific guidelines;
(g) variations concerning a change to or addition of a non-food producing target species;
(h) variations concerning the replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue;
(i) variations concerning the replacement of a strain for a veterinary vaccine against equine influenza;
(j) variations related to changes to the active substance of a seasonal, pre-pandemic or pandemic vaccine against human influenza;
(k) variations related to changes to the withdrawal period for a veterinary medicinal product;
(l) variations related to the replacement or addition of a serotype, strain, antigen or coding sequence or combination of serotypes, strains, antigens or coding sequences for a human coronavirus vaccine.
1. One of the variations in the group is an extension of the marketing authorisation.
2. One of the variations in the group is a major variation of type II; all other variations in the group are variations which are consequential to this major variation of type II.
3. One of the variations in the group is a minor variation of type IB; all other variations in the group are minor variations which are consequential to this minor variation of type IB.
4. All variations in the group relate solely to changes of administrative nature to the summary of product characteristics, labelling and package leaflet or insert.
5. All variations in the group are changes to an Active Substance Master File, Vaccine Antigen Master File or Plasma Master File.
6. All variations in the group relate to a project intended to improve the manufacturing process and the quality of the medicinal product concerned or its active substance(s).
7. All variations in the group are changes affecting the quality of a human pandemic influenza vaccine.
8. All variations in the group are changes to the pharmacovigilance system referred to in points (ia) and (n) of Article 8(3) of Directive 2001/83/EC or points (k) and (o) of Article 12(3) of Directive 2001/82/EC.
9. All variations in the group are consequential to a given urgent safety restriction and submitted in accordance with Article 22.
10. All variations in the group relate to the implementation of a given class labelling.
11. All variations in the group are consequential to the assessment of a given periodic safety update report.
12. All variations in the group are consequential to a given post-authorisation study conducted under the supervision of the holder.
13. All variations in the group are consequential to a specific obligation carried out pursuant to Article 14(7) of Regulation (EC) No 726/2004.
14. All variations in the group are consequential to a specific procedure or condition carried out pursuant to Articles 14(8) or 39(7) of Regulation (EC) No 726/2004, Article 22 of Directive 2001/83/EC or Article 26(3) of Directive 2001/82/EC.
1. A list of all the marketing authorisations affected by the notification or application.
2. A description of all the variations submitted, including:
(a) in the case of minor variations of type IA, the date of implementation for each variation described;
(b) in the case of minor variations of type IA which do not require immediate notification, a description of all minor variations of type IA made in the last 12 months to the terms of the concerned marketing authorisation(s) and which have not been already notified.
3. All necessary documents as listed in the guidelines referred to in point (b) of Article 4(1).
4. Where a variation leads to or is the consequence of other variations to the terms of the same marketing authorisation, a description of the relation between these variations.
5. In the case of variations to centralised marketing authorisations, the relevant fee provided for in Council Regulation (EC) No 297/95 <*>.
6. In the case of variations to marketing authorisations granted by the competent authorities of Member States:
(a) a list of those Member States with an indication of the reference Member State if applicable;
(b) the relevant fees provided for in the applicable national rules in the Member States concerned.
Variations concerning a change to or addition of therapeutic indications.
1. Variations concerning a change to or addition of a non-food producing target species.
2. Variations concerning the replacement or addition of a serotype, strain, antigen or combination of serotypes, strains or antigens for a veterinary vaccine against avian influenza, foot-and-mouth disease or bluetongue.
3. Variations concerning the replacement of a strain for a veterinary vaccine against equine influenza.
the Federal Republic of Germany.
Переход между статьями: Ctrl + ← / →